English

AgeX Therapeutics, Inc.

EDGAR

AGE Registration statement (S-1) · filed 2026-08-24

Annual consolidated revenue for 2025: about USD 130K, using the latest reported figures. The previous period, 2024, was about USD 56K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-6.7 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -11300000 USD Source
Operating Cash Flow: -4600000 USD Source

Free cash flow

-6.73 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -11300000 USD Source
Operating Cash Flow: -4600000 USD Source
Capital Expenditure: 53000 USD Source
Capital Expenditure: 25000 USD Source

Cash and cash equivalents: 23 million USD 2026-06-30 Source
Exact value

23000000 USD
Long-term debt including current maturities: 11.2 million USD 2024-09-30 Source
Exact value

11155000 USD
Shares outstanding: 25.4 million shares 2026-06-30 Source
Exact value

25400000 shares

Reported share-count change

150.37% · 15.3 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

10145000 shares · 2025-06-30· Source
25400000 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-21.2 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -4585000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -19200000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -15800000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -6900000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -6356000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-21.2 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -11900000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -8072000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -18000000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -11900000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -4600000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -11300000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -4600000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

66 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 59000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 46000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 59000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 59000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 25000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 53000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 25000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-21.3 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -11900000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -8072000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -18000000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -11900000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -4600000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -11300000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -4600000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 59000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 46000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 59000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 59000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 25000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 53000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 25000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-24.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2025-12-31
Operating income: 9 of 11 periods available· newest 2025-12-31
Net income: 9 of 11 periods available· newest 2025-12-31
Operating cash flow: 9 of 11 periods available· newest 2025-12-31
Capital expenditure: 8 of 11 periods available· newest 2025-12-31
Total assets: 9 of 11 periods available· newest 2025-12-31
Total liabilities: 9 of 11 periods available· newest 2025-12-31
Current assets: 9 of 11 periods available· newest 2025-12-31
Current liabilities: 8 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 2 of 11 periods available· newest 2022-12-31
Shares outstanding: 9 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+132.1%

Prior period

USD 56,000

2024-01-01 – 2024-12-31
Current period

USD 130,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

130000 − 56000 = 74000 USD

56000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
130000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · AgeX Therapeutics, Inc. · 2025-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Year-over-year change in Revenue: 74000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 130000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/ser-20251231.htm#1397056 Filing: 000170859926000016 Input fundies:Revenue: 56000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/ser-20251231.htm#1397689 Filing: 000170859926000016
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 8.06 million

Prior period

−USD 11.14 million

2024-01-01 – 2024-12-31
Current period

−USD 19.2 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-19200000 − -11141000 = -8059000 USD

-11141000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-19200000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · AgeX Therapeutics, Inc. · 2025-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Year-over-year change in Net income: -8059000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -19200000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/ser-20251231.htm#1672138 Filing: 000170859926000016 Input fundies:NetIncome: -11141000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/ser-20251231.htm#1421884 Filing: 000170859926000016
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 863,000

Prior period

−USD 17.14 million

2024-01-01 – 2024-12-31
Current period

−USD 18 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-18000000 − -17137000 = -863000 USD

-17137000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-18000000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · AgeX Therapeutics, Inc. · 2025-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Year-over-year change in Operating cash flow: -863000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -18000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/ser-20251231.htm#1672349 Filing: 000170859926000016 Input fundies:OperatingCashFlow: -17137000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/ser-20251231.htm#1606941 Filing: 000170859926000016
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+168.2%

Prior period

USD 22,000

2024-01-01 – 2024-12-31
Current period

USD 59,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

59000 − 22000 = 37000 USD

22000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
59000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · AgeX Therapeutics, Inc. · 2025-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Year-over-year change in Capital expenditure: 37000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 59000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/ser-20251231.htm#1608551 Filing: 000170859926000016 Input fundies:CapitalExpenditure: 22000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/ser-20251231.htm#1609108 Filing: 000170859926000016
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 130,000 100% of revenue
Operating costs Derived USD 24.15 million 18,578% of revenue
Operating income −USD 24.02 million −18,478% of revenue
Tax, interest and other Derived −USD 4.82 million −3,709% of revenue
Net income −USD 19.2 million −14,769% of revenue

Cash

Operating cash flow −USD 18 million −13,846% of revenue
Capital expenditure USD 59,000 45% of revenue
Free cash flow Derived −USD 18.06 million −13,892% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2017 Operating loss: operating costs were 575% of revenue.
2018 Operating loss: operating costs were 906% of revenue.
2019 Operating loss: operating costs were 827% of revenue.
2020 Operating loss: operating costs were 2,898% of revenue.
2021 Operating loss: operating costs were 5,609% of revenue.
2022 Operating loss: operating costs were 484% of revenue.
2023 Operating loss: operating costs were 199% of revenue.
2024 Operating loss: operating costs were 30,543% of revenue.
2025 Operating loss: operating costs were 18,578% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2017 2017-01-01 – 2017-12-31	1404000	8067000 Derived	-6663000	-83000 Derived	-6580000	-6286000 Derived	Source 2017-01-01 – 2017-12-31: 1404000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -6663000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -6580000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -6285000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 1000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	1396000	12641000 Derived	-11245000	-3743000 Derived	-7502000	-8016000 Derived	Source 2018-01-01 – 2018-12-31: 1396000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -11245000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -7502000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -7995000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 21000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	1728000	14287000 Derived	-12559000	-405000 Derived	-12154000	-10801000 Derived	Source 2019-01-01 – 2019-12-31: 1728000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -12559000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -12154000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -10160000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 641000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	361000	10461000 Derived	-10100000	765000 Derived	-10865000	-7837000 Derived	Source 2020-01-01 – 2020-12-31: 361000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -10100000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -10865000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -7817000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 20000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	144000	8077000 Derived	-7933000	742000 Derived	-8675000	Unavailable	Source 2021-01-01 – 2021-12-31: 144000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -7933000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -8675000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -7855000 USD Inspect Operating Cash Flow Open source
2022 2022-01-01 – 2022-12-31	591500	2861868 Derived	-2270368	411740 Derived	-2682108	-2085306 Derived	Source 2022-01-01 – 2022-12-31: 591500 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -2270368 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -2682108 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -2075624 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 9682 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	3153000	6282000 Derived	-3129000	-8398000 Derived	5269000	-2980015 Derived	Source 2023-01-01 – 2023-12-31: 3153000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -3129000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: 5269000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -2476000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 504015 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	56000	17104000 Derived	-17048000	-5907000 Derived	-11141000	-17159000 Derived	Source 2024-01-01 – 2024-12-31: 56000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -17048000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -11141000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -17137000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 22000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	130000	24152000 Derived	-24022000	-4822000 Derived	-19200000	-18059000 Derived	Source 2025-01-01 – 2025-12-31: 130000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -24022000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -19200000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -18000000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 59000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 130K 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Revenue	1404000	Revenue: 1404000 Open source
20182018-12-31	Revenue	1396000	Revenue: 1396000 Open source
20192019-12-31	Revenue	1728000	Revenue: 1728000 Open source
20202020-12-31	Revenue	361000	Revenue: 361000 Open source
20212021-12-31	Revenue	144000	Revenue: 144000 Open source
20222022-12-31	Revenue	591500	Revenue: 591500 Open source
20232023-12-31	Revenue	3153000	Revenue: 3153000 Open source
20242024-12-31	Revenue	56000	Revenue: 56000 Open source
20252025-12-31	Revenue	130000	Revenue: 130000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

132.1% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Year over year	No prior comparable period	Revenue: 1404000 Open source
20182018-12-31	Year over year	-0.6%	Revenue: 1396000 Open source Revenue: 1404000 Open source
20192019-12-31	Year over year	23.8%	Revenue: 1728000 Open source Revenue: 1396000 Open source
20202020-12-31	Year over year	-79.1%	Revenue: 361000 Open source Revenue: 1728000 Open source
20212021-12-31	Year over year	-60.1%	Revenue: 144000 Open source Revenue: 361000 Open source
20222022-12-31	Year over year	310.8%	Revenue: 591500 Open source Revenue: 144000 Open source
20232023-12-31	Year over year	433.1%	Revenue: 3153000 Open source Revenue: 591500 Open source
20242024-12-31	Year over year	-98.2%	Revenue: 56000 Open source Revenue: 3153000 Open source
20252025-12-31	Year over year	132.1%	Revenue: 130000 Open source Revenue: 56000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -18,478.5% 2025

Net margin -14,769.2% 2025

Free cash flow margin -13,891.5% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Operating margin	-474.6%	Operating Income: -6663000 Open source Revenue: 1404000 Open source
20182018-12-31	Operating margin	-805.5%	Operating Income: -11245000 Open source Revenue: 1396000 Open source
20192019-12-31	Operating margin	-726.8%	Operating Income: -12559000 Open source Revenue: 1728000 Open source
20202020-12-31	Operating margin	-2,797.8%	Operating Income: -10100000 Open source Revenue: 361000 Open source
20212021-12-31	Operating margin	-5,509%	Operating Income: -7933000 Open source Revenue: 144000 Open source
20222022-12-31	Operating margin	-383.8%	Operating Income: -2270368 Open source Revenue: 591500 Open source
20232023-12-31	Operating margin	-99.2%	Operating Income: -3129000 Open source Revenue: 3153000 Open source
20242024-12-31	Operating margin	-30,442.9%	Operating Income: -17048000 Open source Revenue: 56000 Open source
20252025-12-31	Operating margin	-18,478.5%	Operating Income: -24022000 Open source Revenue: 130000 Open source
20172017-12-31	Net margin	-468.7%	Net Income: -6580000 Open source Revenue: 1404000 Open source
20182018-12-31	Net margin	-537.4%	Net Income: -7502000 Open source Revenue: 1396000 Open source
20192019-12-31	Net margin	-703.4%	Net Income: -12154000 Open source Revenue: 1728000 Open source
20202020-12-31	Net margin	-3,009.7%	Net Income: -10865000 Open source Revenue: 361000 Open source
20212021-12-31	Net margin	-6,024.3%	Net Income: -8675000 Open source Revenue: 144000 Open source
20222022-12-31	Net margin	-453.4%	Net Income: -2682108 Open source Revenue: 591500 Open source
20232023-12-31	Net margin	167.1%	Net Income: 5269000 Open source Revenue: 3153000 Open source
20242024-12-31	Net margin	-19,894.6%	Net Income: -11141000 Open source Revenue: 56000 Open source
20252025-12-31	Net margin	-14,769.2%	Net Income: -19200000 Open source Revenue: 130000 Open source
20172017-12-31	Free cash flow margin	-447.7%	Revenue: 1404000 Open source Operating Cash Flow: -6285000 Open source Capital Expenditure: 1000 Open source
20182018-12-31	Free cash flow margin	-574.2%	Revenue: 1396000 Open source Operating Cash Flow: -7995000 Open source Capital Expenditure: 21000 Open source
20192019-12-31	Free cash flow margin	-625.1%	Revenue: 1728000 Open source Operating Cash Flow: -10160000 Open source Capital Expenditure: 641000 Open source
20202020-12-31	Free cash flow margin	-2,170.9%	Revenue: 361000 Open source Operating Cash Flow: -7817000 Open source Capital Expenditure: 20000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 144000 Open source Operating Cash Flow: -7855000 Open source
20222022-12-31	Free cash flow margin	-352.5%	Revenue: 591500 Open source Operating Cash Flow: -2075624 Open source Capital Expenditure: 9682 Open source
20232023-12-31	Free cash flow margin	-94.5%	Revenue: 3153000 Open source Operating Cash Flow: -2476000 Open source Capital Expenditure: 504015 Open source
20242024-12-31	Free cash flow margin	-30,641.1%	Revenue: 56000 Open source Operating Cash Flow: -17137000 Open source Capital Expenditure: 22000 Open source
20252025-12-31	Free cash flow margin	-13,891.5%	Revenue: 130000 Open source Operating Cash Flow: -18000000 Open source Capital Expenditure: 59000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -18M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Operating cash flow	-6285000	Operating Cash Flow: -6285000 Open source
20182018-12-31	Operating cash flow	-7995000	Operating Cash Flow: -7995000 Open source
20192019-12-31	Operating cash flow	-10160000	Operating Cash Flow: -10160000 Open source
20202020-12-31	Operating cash flow	-7817000	Operating Cash Flow: -7817000 Open source
20212021-12-31	Operating cash flow	-7855000	Operating Cash Flow: -7855000 Open source
20222022-12-31	Operating cash flow	-2075624	Operating Cash Flow: -2075624 Open source
20232023-12-31	Operating cash flow	-2476000	Operating Cash Flow: -2476000 Open source
20242024-12-31	Operating cash flow	-17137000	Operating Cash Flow: -17137000 Open source
20252025-12-31	Operating cash flow	-18000000	Operating Cash Flow: -18000000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -18.1M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Free cash flow	-6286000	Operating Cash Flow: -6285000 Open source Capital Expenditure: 1000 Open source
20182018-12-31	Free cash flow	-8016000	Operating Cash Flow: -7995000 Open source Capital Expenditure: 21000 Open source
20192019-12-31	Free cash flow	-10801000	Operating Cash Flow: -10160000 Open source Capital Expenditure: 641000 Open source
20202020-12-31	Free cash flow	-7837000	Operating Cash Flow: -7817000 Open source Capital Expenditure: 20000 Open source
20212021-12-31	Free cash flow	Unavailable	Operating Cash Flow: -7855000 Open source
20222022-12-31	Free cash flow	-2085306	Operating Cash Flow: -2075624 Open source Capital Expenditure: 9682 Open source
20232023-12-31	Free cash flow	-2980015	Operating Cash Flow: -2476000 Open source Capital Expenditure: 504015 Open source
20242024-12-31	Free cash flow	-17159000	Operating Cash Flow: -17137000 Open source Capital Expenditure: 22000 Open source
20252025-12-31	Free cash flow	-18059000	Operating Cash Flow: -18000000 Open source Capital Expenditure: 59000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

100.5% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Liabilities / assets	13.6%	Total Liabilities: 1312000 Open source Total Assets: 9631000 Open source
20182018-12-31	Liabilities / assets	22.9%	Total Liabilities: 2440000 Open source Total Assets: 10671000 Open source
20192019-12-31	Liabilities / assets	64.8%	Total Liabilities: 4825000 Open source Total Assets: 7442000 Open source
20202020-12-31	Liabilities / assets	237.5%	Total Liabilities: 9321000 Open source Total Assets: 3925000 Open source
20212021-12-31	Liabilities / assets	476.5%	Total Liabilities: 15029000 Open source Total Assets: 3154000 Open source
20222022-12-31	Liabilities / assets	372.3%	Total Liabilities: 3194703 Open source Total Assets: 858042 Open source
20232023-12-31	Liabilities / assets	54.2%	Total Liabilities: 4858000 Open source Total Assets: 8968000 Open source
20242024-12-31	Liabilities / assets	92.4%	Total Liabilities: 6216000 Open source Total Assets: 6724000 Open source
20252025-12-31	Liabilities / assets	100.5%	Total Liabilities: 6988000 Open source Total Assets: 6951000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.71× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Current assets / current liabilities	Not reported	Current Assets: 7593000 Open source
20182018-12-31	Current assets / current liabilities	3.22×	Current Assets: 7853000 Open source Current Liabilities: 2440000 Open source
20192019-12-31	Current assets / current liabilities	1.23×	Current Assets: 4054000 Open source Current Liabilities: 3297000 Open source
20202020-12-31	Current assets / current liabilities	0.43×	Current Assets: 2283000 Open source Current Liabilities: 5357000 Open source
20212021-12-31	Current assets / current liabilities	0.25×	Current Assets: 2234000 Open source Current Liabilities: 8967000 Open source
20222022-12-31	Current assets / current liabilities	1.25×	Current Assets: 548575 Open source Current Liabilities: 437686 Open source
20232023-12-31	Current assets / current liabilities	5.39×	Current Assets: 7619000 Open source Current Liabilities: 1413000 Open source
20242024-12-31	Current assets / current liabilities	2.4×	Current Assets: 5676000 Open source Current Liabilities: 2366000 Open source
20252025-12-31	Current assets / current liabilities	1.71×	Current Assets: 6080000 Open source Current Liabilities: 3563000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2017-01-01 – 2017-12-31	−USD 6.58 million Exact value Exact value: -6580000 USD 2017-01-01 – 2017-12-31: -6580000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AgeX Therapeutics, Inc. · 2017-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Net Income: -6580000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -6580000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315219004614/age-20181231.xml#98382 Filing: 000149315219004614 The citation records this snapshot. The page link may show a newer release later.	−USD 6.29 million Exact value Exact value: -6285000 USD 2017-01-01 – 2017-12-31: -6285000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AgeX Therapeutics, Inc. · 2017-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Operating Cash Flow: -6285000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6285000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315219004614/age-20181231.xml#130326 Filing: 000149315219004614 The citation records this snapshot. The page link may show a newer release later.	USD 1,000 Exact value Exact value: 1000 USD 2017-01-01 – 2017-12-31: 1000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AgeX Therapeutics, Inc. · 2017-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Capital Expenditure: 1000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315219004614/age-20181231.xml#132356 Filing: 000149315219004614 The citation records this snapshot. The page link may show a newer release later.	−USD 6.29 million Calculation and evidence -6285000 − 1000 USD Exact free cash flow: -6286000 USD 2017-01-01 – 2017-12-31: -6285000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 1000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AgeX Therapeutics, Inc. · 2017-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Free cash flow: -6286000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6285000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315219004614/age-20181231.xml#130326 Filing: 000149315219004614 Input fundies:CapitalExpenditure: 1000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315219004614/age-20181231.xml#132356 Filing: 000149315219004614 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 7.5 million Exact value Exact value: -7502000 USD 2018-01-01 – 2018-12-31: -7502000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AgeX Therapeutics, Inc. · 2018-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Net Income: -7502000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7502000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315220005509/age-20191231.xml#436275 Filing: 000149315220005509 The citation records this snapshot. The page link may show a newer release later.	−USD 8 million Exact value Exact value: -7995000 USD 2018-01-01 – 2018-12-31: -7995000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AgeX Therapeutics, Inc. · 2018-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Operating Cash Flow: -7995000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7995000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315220005509/age-20191231.xml#95322 Filing: 000149315220005509 The citation records this snapshot. The page link may show a newer release later.	USD 21,000 Exact value Exact value: 21000 USD 2018-01-01 – 2018-12-31: 21000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AgeX Therapeutics, Inc. · 2018-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Capital Expenditure: 21000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 21000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315220005509/age-20191231.xml#97642 Filing: 000149315220005509 The citation records this snapshot. The page link may show a newer release later.	−USD 8.02 million Calculation and evidence -7995000 − 21000 USD Exact free cash flow: -8016000 USD 2018-01-01 – 2018-12-31: -7995000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 21000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AgeX Therapeutics, Inc. · 2018-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Free cash flow: -8016000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7995000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315220005509/age-20191231.xml#95322 Filing: 000149315220005509 Input fundies:CapitalExpenditure: 21000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315220005509/age-20191231.xml#97642 Filing: 000149315220005509 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 12.15 million Exact value Exact value: -12154000 USD 2019-01-01 – 2019-12-31: -12154000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AgeX Therapeutics, Inc. · 2019-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Net Income: -12154000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12154000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315221007461/age-20201231.xml#142592 Filing: 000149315221007461 The citation records this snapshot. The page link may show a newer release later.	−USD 10.16 million Exact value Exact value: -10160000 USD 2019-01-01 – 2019-12-31: -10160000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AgeX Therapeutics, Inc. · 2019-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Operating Cash Flow: -10160000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10160000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315221007461/age-20201231.xml#149933 Filing: 000149315221007461 The citation records this snapshot. The page link may show a newer release later.	USD 641,000 Exact value Exact value: 641000 USD 2019-01-01 – 2019-12-31: 641000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AgeX Therapeutics, Inc. · 2019-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Capital Expenditure: 641000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 641000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315221007461/age-20201231.xml#156266 Filing: 000149315221007461 The citation records this snapshot. The page link may show a newer release later.	−USD 10.8 million Calculation and evidence -10160000 − 641000 USD Exact free cash flow: -10801000 USD 2019-01-01 – 2019-12-31: -10160000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 641000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AgeX Therapeutics, Inc. · 2019-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Free cash flow: -10801000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10160000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315221007461/age-20201231.xml#149933 Filing: 000149315221007461 Input fundies:CapitalExpenditure: 641000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315221007461/age-20201231.xml#156266 Filing: 000149315221007461 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 10.87 million Exact value Exact value: -10865000 USD 2020-01-01 – 2020-12-31: -10865000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AgeX Therapeutics, Inc. · 2020-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Net Income: -10865000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10865000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315222008028/form10-k.htm#1262495 Filing: 000149315222008028 The citation records this snapshot. The page link may show a newer release later.	−USD 7.82 million Exact value Exact value: -7817000 USD 2020-01-01 – 2020-12-31: -7817000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AgeX Therapeutics, Inc. · 2020-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Operating Cash Flow: -7817000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7817000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315222008028/form10-k.htm#1468953 Filing: 000149315222008028 The citation records this snapshot. The page link may show a newer release later.	USD 20,000 Exact value Exact value: 20000 USD 2020-01-01 – 2020-12-31: 20000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AgeX Therapeutics, Inc. · 2020-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Capital Expenditure: 20000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 20000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315222008028/form10-k.htm#1477596 Filing: 000149315222008028 The citation records this snapshot. The page link may show a newer release later.	−USD 7.84 million Calculation and evidence -7817000 − 20000 USD Exact free cash flow: -7837000 USD 2020-01-01 – 2020-12-31: -7817000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 20000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AgeX Therapeutics, Inc. · 2020-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Free cash flow: -7837000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7817000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315222008028/form10-k.htm#1468953 Filing: 000149315222008028 Input fundies:CapitalExpenditure: 20000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315222008028/form10-k.htm#1477596 Filing: 000149315222008028 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 8.68 million Exact value Exact value: -8675000 USD 2021-01-01 – 2021-12-31: -8675000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AgeX Therapeutics, Inc. · 2021-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Net Income: -8675000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8675000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315223040779/forms-4.htm#5942849 Filing: 000149315223040779 The citation records this snapshot. The page link may show a newer release later.	−USD 7.86 million Exact value Exact value: -7855000 USD 2021-01-01 – 2021-12-31: -7855000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AgeX Therapeutics, Inc. · 2021-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Operating Cash Flow: -7855000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7855000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315223040779/forms-4.htm#6133502 Filing: 000149315223040779 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2022-01-01 – 2022-12-31	−USD 2.68 million Exact value Exact value: -2682108 USD 2022-01-01 – 2022-12-31: -2682108 USD Inspect Net Income Open source Share or cite Citation for Net Income · AgeX Therapeutics, Inc. · 2022-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Net Income: -2682108 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2682108 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315224017773/forms-1.htm#3297660 Filing: 000149315224017773 The citation records this snapshot. The page link may show a newer release later.	−USD 2.08 million Exact value Exact value: -2075624 USD 2022-01-01 – 2022-12-31: -2075624 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AgeX Therapeutics, Inc. · 2022-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Operating Cash Flow: -2075624 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2075624 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315224017773/forms-1.htm#2863448 Filing: 000149315224017773 The citation records this snapshot. The page link may show a newer release later.	USD 9,682 Exact value Exact value: 9682 USD 2022-01-01 – 2022-12-31: 9682 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AgeX Therapeutics, Inc. · 2022-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Capital Expenditure: 9682 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9682 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315224017773/forms-1.htm#2866361 Filing: 000149315224017773 The citation records this snapshot. The page link may show a newer release later.	−USD 2.09 million Calculation and evidence -2075624 − 9682 USD Exact free cash flow: -2085306 USD 2022-01-01 – 2022-12-31: -2075624 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 9682 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AgeX Therapeutics, Inc. · 2022-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Free cash flow: -2085306 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2075624 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315224017773/forms-1.htm#2863448 Filing: 000149315224017773 Input fundies:CapitalExpenditure: 9682 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315224017773/forms-1.htm#2866361 Filing: 000149315224017773 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	USD 5.27 million Exact value Exact value: 5269000 USD 2023-01-01 – 2023-12-31: 5269000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AgeX Therapeutics, Inc. · 2023-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Net Income: 5269000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: 5269000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000027/age-20241231.htm#1420759 Filing: 000170859925000027 The citation records this snapshot. The page link may show a newer release later.	−USD 2.48 million Exact value Exact value: -2476000 USD 2023-01-01 – 2023-12-31: -2476000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AgeX Therapeutics, Inc. · 2023-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Operating Cash Flow: -2476000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2476000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000027/age-20241231.htm#1532821 Filing: 000170859925000027 The citation records this snapshot. The page link may show a newer release later.	USD 504,015 Exact value Exact value: 504015 USD 2023-01-01 – 2023-12-31: 504015 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AgeX Therapeutics, Inc. · 2023-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Capital Expenditure: 504015 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 504015 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315224017773/forms-1.htm#2865901 Filing: 000149315224017773 The citation records this snapshot. The page link may show a newer release later.	−USD 2.98 million Calculation and evidence -2476000 − 504015 USD Exact free cash flow: -2980015 USD 2023-01-01 – 2023-12-31: -2476000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 504015 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AgeX Therapeutics, Inc. · 2023-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Free cash flow: -2980015 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2476000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000027/age-20241231.htm#1532821 Filing: 000170859925000027 Input fundies:CapitalExpenditure: 504015 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000149315224017773/forms-1.htm#2865901 Filing: 000149315224017773 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 11.14 million Exact value Exact value: -11141000 USD 2024-01-01 – 2024-12-31: -11141000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AgeX Therapeutics, Inc. · 2024-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Net Income: -11141000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11141000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/ser-20251231.htm#1421884 Filing: 000170859926000016 The citation records this snapshot. The page link may show a newer release later.	−USD 17.14 million Exact value Exact value: -17137000 USD 2024-01-01 – 2024-12-31: -17137000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AgeX Therapeutics, Inc. · 2024-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Operating Cash Flow: -17137000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -17137000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/ser-20251231.htm#1606941 Filing: 000170859926000016 The citation records this snapshot. The page link may show a newer release later.	USD 22,000 Exact value Exact value: 22000 USD 2024-01-01 – 2024-12-31: 22000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AgeX Therapeutics, Inc. · 2024-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Capital Expenditure: 22000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 22000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/ser-20251231.htm#1609108 Filing: 000170859926000016 The citation records this snapshot. The page link may show a newer release later.	−USD 17.16 million Calculation and evidence -17137000 − 22000 USD Exact free cash flow: -17159000 USD 2024-01-01 – 2024-12-31: -17137000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 22000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AgeX Therapeutics, Inc. · 2024-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Free cash flow: -17159000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -17137000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/ser-20251231.htm#1606941 Filing: 000170859926000016 Input fundies:CapitalExpenditure: 22000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/ser-20251231.htm#1609108 Filing: 000170859926000016 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 19.2 million Exact value Exact value: -19200000 USD 2025-01-01 – 2025-12-31: -19200000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AgeX Therapeutics, Inc. · 2025-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Net Income: -19200000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19200000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/ser-20251231.htm#1672138 Filing: 000170859926000016 The citation records this snapshot. The page link may show a newer release later.	−USD 18 million Exact value Exact value: -18000000 USD 2025-01-01 – 2025-12-31: -18000000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AgeX Therapeutics, Inc. · 2025-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Operating Cash Flow: -18000000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -18000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/ser-20251231.htm#1672349 Filing: 000170859926000016 The citation records this snapshot. The page link may show a newer release later.	USD 59,000 Exact value Exact value: 59000 USD 2025-01-01 – 2025-12-31: 59000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AgeX Therapeutics, Inc. · 2025-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Capital Expenditure: 59000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 59000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/ser-20251231.htm#1608551 Filing: 000170859926000016 The citation records this snapshot. The page link may show a newer release later.	−USD 18.06 million Calculation and evidence -18000000 − 59000 USD Exact free cash flow: -18059000 USD 2025-01-01 – 2025-12-31: -18000000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 59000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AgeX Therapeutics, Inc. · 2025-12-31 AgeX Therapeutics, Inc. (edgar:1708599) Free cash flow: -18059000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:29:51Z Snapshot: 2490355e18e2c9771708fe6cead585e112ed54a7f151d78865fa4ad66f0f02ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1708599?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -18000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/ser-20251231.htm#1672349 Filing: 000170859926000016 Input fundies:CapitalExpenditure: 59000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/ser-20251231.htm#1608551 Filing: 000170859926000016 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

60 filings · 2,411 latest values · 2,411 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001708599, 1708599, AGE, SE, SER, edgar:1708599

Also known as AgeX Therapeutics, Inc., AgeX Therapeutics, Inc., SERINA THERAPEUTICS, INC., Serina Therapeutics, Inc.

AgeX Therapeutics, Inc.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation